Deep, focused following-era sequencing has disclosed that subclonal mutations (i.e., those existing in only a portion of tumor cells) is often detected for all driver genes and they are connected with fast ailment development and poor final result.11–13 This is especially applicable for TP53 mutations provided The reality that, as spelled out und